Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 323Leukemia, Myeloid, Acute 276Leukemia, Myelogenous, Chronic, BCR-ABL Positive 244Leukemia 116Myeloproliferative Disorders 106Primary Myelofibrosis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Leukemia, Myelomonocytic, Chronic 78Polycythemia Vera 73Hematologic Neoplasms 67Multiple Myeloma 50Neoplasms 41Lymphoma, Non-Hodgkin 40Thrombocythemia, Essential 39Hematologic Diseases 38Leukemia, Lymphocytic, Chronic, B-Cell 37Recurrence 35Lymphoma 32Leukemia, Myeloid, Chronic-Phase 31Mastocytosis, Systemic 26Bone Marrow Diseases 25Leukemia, Myeloid 23Blast Crisis 23Anemia, Refractory, with Excess of Blasts 23Hodgkin Disease 21Bronchiolitis Obliterans Syndrome 16Mastocytosis 15Philadelphia Chromosome 14Leukemia, Mast-Cell 13Graft vs Host Disease 13

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Translocation, Genetic × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡